Table 2.
In-vitro and clinical studies investigating miR-155 levels in COVID-19
| Authors | Type of study | Result |
|---|---|---|
| Wyler et al. [88] | In-vitro: SARS-CoV-2- infected Calu-3 cells | Ten-fold upregulation of the miR-155 host gene (MIR155HG) and a 3–16-fold increase of miR-155 |
| Haroun et al. [90] | Clinical study | Increased miR-155 expression level in COVID-19 patients vs. controls, in severe vs. moderate COVID-19 patients, and in non-survival vs. survival COVID-19 patients |
| Abbasi-Kolli et al. [91] | Clinical study | Significantly increased miR-155-5p levels in the acute phase of COVID-19 vs. a healthy control group |
| Garg et al. [92] | Clinical study | Significantly increased miR-155 levels in COVID‐19 patients vs. healthy controls. MiR-155 levels could distinguish between COVID‐19 and Influenza‐acute respiratory distress syndrome (ARDS) groups |
| Donyavi et al. [93] | Clinical study | Significantly upregulated miR-155-5p expression level in the COVID-19 group vs. controls. Significant inverse correlation between miR-155-5p and SARS-CoV-2 N-gene and RdRp-gene |
| Gedikbasi et al. [94] | Clinical study |
Significantly upregulated miR-155-5p levels in COVID-19 patients and associated with disease severity SOCS1 expression robustly and negatively correlated with miR-155 |
| Eyileten et al. [95] | Clinical study | MiR-155-5p expression levels differed between healthy individuals and COVID-19 patients and showed increasing trend at day-7 and day-21 after admission |
| Li et al. [96] | Clinical study | Markedly elevated miR-155 in mild/moderate COVID-19 disease vs. severe/critical disease and negative controls |
| Gaytán-Pacheco et al. [97] | Clinical study | Significant upregulation of miR-155 in severe COVID-19 patients versus negative controls |
| Giannella et al. [98] | Clinical study | Significantly downregulated miR-155 levels in severe vs. mild COVID-19, in ICU vs. non-ICU. Predicted increased risk of COVID-19-related sequelae and/or death |
| Kassif-Lerner et al. [99] | Clinical study | 2.5-fold and fivefold less circulating miR-155 in mild and severe COVID-19 disease, respectively, vs. healthy people |
COVID-19 coronavirus disease 2019, ICU intensive care unit, miR-155, MicroRNA-155, SARS-CoV-2 severe acute respiratory coronavirus 2